MWMichael Will

Michael Will

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Will has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Scalable Computation of Topological Abstractions for Scalar Data

    by M. Will, J. Lukasczyk, J. Tierny, A. Gyulassy, G. H. Weber, H. Carr, C. Garth

    Topological data analysis has become an important tool for large scale scalar data analysis and visualization, efficiently extracting the inherent structure and features of interest of the data. However, with growing dataset sizes and complexity, it is increasingly becoming infeasible to compute topological abstractions of interest in serial and on single machines. This paper presents the state of the art in the scalable computation of topological abstractions on scalar data, in shared memory parallel on single machines, and in distributed memory parallel on multiple machines. We highlight results for set‐based, graph‐based and complex‐based abstractions and organize the state of the art based on this taxonomy. The paper identifies parallelization and distribution techniques common in topological algorithms and highlights further areas of interest with underdeveloped efforts.

  • TTK is Getting MPI-Ready

    by Eve Le Guillou, Michael Will, Pierre Guillou, Jonas Lukasczyk, Pierre Fortin, Christoph Garth, Julien Tierny

    This system paper documents the technical foundations for the extension of the Topology ToolKit (TTK) to distributed-memory parallelism with the Message Passing Interface (MPI). While several recent papers introduced topology-based approaches for distributed-memory environments, these were reporting experiments obtained with tailored, mono-algorithm implementations. In contrast, we describe in this paper a versatile approach (supporting both triangulated domains and regular grids) for the support of topological analysis pipelines , i.e., a sequence of topological algorithms interacting together, possibly on distinct numbers of processes. While developing this extension, we faced several algorithmic and software engineering challenges, which we document in this paper. Specifically, we describe an MPI extension of TTK’s data structure for triangulation representation and traversal, a central component to the global performance and generality of TTK’s topological implementations. We also introduce an intermediate interface between TTK and MPI, both at the global pipeline level, and at the fine-grain algorithmic level. We provide a taxonomy for the distributed-memory topological algorithms supported by TTK, depending on their communication needs and provide examples of hybrid MPI+thread parallelizations. Detailed performance analyses show that parallel efficiencies range from 20% to 80% (depending on the algorithms), and that the MPI-specific preconditioning introduced by our framework induces a negligible computation time overhead. We illustrate the new distributed-memory capabilities of TTK with an example of advanced analysis pipeline, combining multiple algorithms, run on the largest publicly available dataset we have found (120 billion vertices) on a standard cluster with 64 nodes (for a total of 1536 cores). Finally, we provide a roadmap for the completion of TTK’s MPI extension, along with generic recommendations for each algorithm communication category.


  • Open Access

    Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors

    by V. Boni, J. Garcia-Corbacho, P.A. Ott, D.C. Cho, K.A. Autio, N. Uboha, A.I. Spira, R. Humphrey, M. Will, A. Naing, et al.

    Background: Antibodies (Abs) against programmed cell death ligand-1 (PD-L1) have improved survival in many types of cancer when used as monotherapy. However, anti–PD-L1 agents can be associated with high-grade immune-related adverse events (irAEs), particularly when used in combination with other anticancer agents. CX-072 is an anti–PD-L1 Probody™ therapeutic (Pb-Tx) designed to be preferentially activated by proteases in the tumor microenvironment and not in healthy tissue. Preclinically, Pb-Tx exhibited anticancer activity of the parent Ab with reduced toxicities in models of autoimmunity.


  • Open Access

    Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors

    by R. Plummer, R.E. Sanborn, E.G.E. de Vries, P. Lorusso, H.-T. Arkenau, N. Uboha, J. Wydmanski, M.J. Fidler, V. Boni, J. Garcia-Corbacho, et al.

    Background: Combination treatment with PD-1 + CTLA-4 checkpoint inhibitors shows improvement in breadth, depth, and durability of response, coupled with a disproportionate increase in immune-related adverse events (irAE). CX-072, a Probody™ therapeutic (Pb-Tx) directed against PD-L1, is designed to be preferentially activated by tumor-associated proteases and not in healthy tissue. Preclinically, anti–PD-1 Pb-Tx + anti–CTLA-4 showed comparable efficacy with improved safety compared to the non–Pb-Tx combination control. This dose-escalation cohort examines safety and tolerability of CX-072 (anti-PD-L1 Pb-Tx) + the CTLA-4 inhibitor ipi in pts with advanced solid tumors.


  • Open Access

    PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors

    by J. Garcia-Corbacho, A. Spira, V. Boni, J. Feliu, M. Middleton, H. Burris, A. Yang Weaver, M. Will, J. Harding, F. Meric-Bernstam, et al.

    Background: CX-2009 is a novel recombinant Probody™ drug conjugate (PDC) derived from a humanized monoclonal antibody (mAb) against CD166 and conjugated to N-succinimidyl 4-(2-pyridyldithio) butanoate-N2′-deacetyl-N2′-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (SPDB-DM4, licensed from Immunogen), a potent microtubule inhibitor. PDCs are fully recombinant mAb prodrugs designed to remain inactive until they are cleaved into an active mAb by tumor-associated proteases. This tumor-specific activation allows PDCs to target highly and homogeneously expressed tumor antigens while avoiding binding to these same targets on healthy tissue. An example is CD166 (also referred to as activated leukocyte cell adhesion molecule [ALCAM]), which is highly expressed in multiple cancers but also in healthy tissue. In preclinical studies, CX-2009 exhibited antitumor activity and reduced peripheral binding compared to the corresponding anti-CD166 ADC.